NCT06377657Completed
Oxidative and Antioxidant Indices to HIIT and Aloe Vera Supplementation in Patients With T2DM
METRNL Response, Plasma Oxidative and Antioxidant Indices to HIIT and Aloe Vera Supplementation in Patients With Diabetes Type 2
Source: ClinicalTrials.gov · Last updated 22 Apr 2024
Brief summary (registry, in English)
Diabetes is a prevalent metabolic disease that leads to increased blood sugar levels due to insulin shortage or resistance. Type 2 diabetes is often linked to obesity, which can increase insulin resistance. Meteorin-like protein (METRNL) is a new secreted protein that affects insulin sensitivity and has been found to be negatively related to serum glucose levels in people with diabetes. Oxidative stress in diabetics can stimulate the production of inflammatory mediators, increasing the activity of the antioxidant system. Aloe vera, a widely used plant, has been used for treating diabetes, wound healing, tumors, and inflammatory bowel disease. It has anti-inflammatory, antioxidant, neuroprotective, antidepressant, and memory-enhancing effects. Exercise can improve diabetic patients' conditions by increasing the expression of GLUT4 protein and skeletal muscle. High-intensity interval training has been shown to increase the expression of the METORIN gene in human subjects and decrease MDA in type 2 diabetic patients. However, no studies have examined the simultaneous effect of exercise and Aloe vera on diabetes indicators. The present study aims to investigate the response of METRNL and some oxidative and antioxidant plasma indicators to high-intensity interval training and Aloe vera supplementation in type 2 diabetic men. The findings indicate that exercise and consumption of plants with anti-inflammatory and antioxidant properties can be effective in modulating the pathological effects of diabetes and increasing insulin sensitivity.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 44 (actual)
- First submitted
- 23 Mar 2024
- Start date
- 15 Jan 2022
- Primary completion date
- 21 Jun 2023
- Lead sponsor
- University of Nis
- Diseases
- Type 2 diabetes
- NCT number
- NCT06377657
What you commit to
- Study type: Interventional
- Participants enrolled: 44
- From 15 Jan 2022 to the primary completion date, 21 Jun 2023
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- History of diabetic complications (the final stage of proliferative diabetic retinopathy, or subsequent overt nephropathy, diabetic ketoacidosis, or severe diabetic neuropathy)
Lab values
- Fasting glucose above 270 mg / dL
- Hereditary glucose and galactose malabsorption
Other
- Exogenous insulin
Who the study is looking for
- Male participants who have been diagnosed with T2DM at least 3 months prior to the start of the study according to standard criteria
- Inactive participants according to the International Physical Activity Questionnaire (IPAQ)
- Participants receiving stable medical therapy for T2DM, excluding those on exogenous insulin therapy
- Participants who were free from injuries or chronic health conditions that could limit their ability to safely participate in an intense exercise program were included in the study
Age in the registry: 25 years to 40 years · Sex: Male · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Department of Sport Physiology, Faculty of Sport and Physical education, Islamic Azad University of Ayatollah Amoli, Amol, Iran Coordinator of this site? Confirm its status | Āmol | Iran | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.